Follow-Up To Long-Term Care Pharmacy Listening Session
Jane A. Axelrad
Associate Director for Policy (HFD-005)
Center for Drug Evaluation and Research
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, Maryland 20993
Re: Follow-Up To Long-Term Care Pharmacy Listening Session
Dear Ms. Axelrad:
The Senior Care Pharmacy Coalition (SCPC), one of the organizations that participated in the Food and Drug Administration’s (FDA) August 26, 2015 “listening session” on long-term care (LTC) pharmacy (the Listening Session), submits the following supplemental information that FDA requested to further
elucidate LTC pharmacy issues and the potential impacts of FDA’s Draft Repackaging Guidance on LTC patient care.
At the meeting, FDA requested additional information from the industry, including written copies of opening statements; representative text of state “emergency kit” (or e-kit) laws; certain perspectives on product expiration dating; and definitional characteristics that FDA could use to identify LTC pharmacies. We are pleased to respond to that request, and have appended to this letter: (1) the written version of the statement that Robert Warnock made on behalf of the SCPC during the Listening Session (Attachment 1); (2) a summary and certain excerpts of state e-kit laws (Attachment 2); and (3) copies of federal definitions and policies appropriate to define LTC pharmacies (Attachment 3).
In addition to information addressing FDA’s requests for data that were raised at the Listening Session (summarized in Section I below and included as attachments), we also provide specific policy recommendations for ways in which the Draft Guidance could be amended that we believe both meets the
agency’s policy goals and addresses the operational challenges faced by the regulated LTC pharmacy community. Thus, in Section II below, we provide three specific proposed changes to the Draft Guidance, addressing prepackaging generally, automated dispensing, and emergency kits.
Recent Posts
-
SCPC Releases Statement in Support of Government Accountability Office (GAO) Report on the Inflation Reduction Act
SCPC has repeatedly warned about the impact of the Inflation Reduction Act’s (IRA) mandatory Medicare drug price negotiations on LTC pharmacies and the millions of vulnerable seniors they serve. We are glad the Government Accountability Office (GAO) is examining how these policies are affecting pharmacies, particularly LTC pharmacies, which already operate under a broken reimbursement model that often requires them to dispense many of the most commonly used medications at a loss.
-
SCPC Applauds President Trump’s Executive Order Calling on HHS and Congress to Improve the IRA, Rein In PBMs and Lower Drug Costs
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care (LTC) pharmacy community, released the following statement applauding President Trump’s recent Executive Order aimed at improving the Inflation Reduction Act (IRA), lowering drug prices and addressing the harmful actions of PBMs. “For far too long, pharmacy benefit managers (PBMs) have taken […]
-
60 percent of LTC pharmacies warn of closure amid major drug pricing changes
Facing deep losses on high-demand medications, 85% of long-term care pharmacies say they will limit essential services and 60% will close locations without changes to Medicare drug pricing efforts. Those are among the “unintended consequences” revealed in a Senior Care Pharmacy Coalition survey released Wednesday. The trade association has been increasingly vocal about pricing changes set to go into effect in January.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.